Premium
Targeting imipramine dose in children with depression
Author(s) -
Sallee Floyd,
Stiller Richard,
Perel James,
Rancurello Michael
Publication year - 1986
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.1986.130
Subject(s) - imipramine , depression (economics) , pharmacokinetics , dosing , metabolite , medicine , plasma concentration , population , active metabolite , pharmacology , alternative medicine , environmental health , pathology , economics , macroeconomics
The response to imipramine (IMI) in children with depression has been shown to correlate with total levels of IMI plus its active metabolite desmethylimipramine (DMI). The pharmacokinetics of IMI + DMI in children with depression are examined, and the single‐point prediction of steady‐state IMI + DMI levels at minimum therapeutic concentrations for prepubertal depression is proposed. With a single, 25 mg oral dose of IMI, a plasma concentration of IMI + DMI 24 hours after dosing correlates (r = 0.92) with steady‐state IMI + DMI levels in children with depression receiving 3 mg/kg/day IMI. The targeting of IMI dose in the child population with depression to rapidly achieve a minimum therapeutic concentration is shown to be feasible and reliable within theoretic limits. Clinical Pharmacology and Therapeutics (1986) 40, 8–13; doi: 10.1038/clpt.1986.130